SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Curing HCV: Mission Accomplished
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
The Burden of Liver Disease Among Persons With Hepatitis C in the United States
Monina Klevens
US Centers for Disease Control and Prevention, Atlanta, GA, United States
High Efficacy of Daclatasvir/Asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30)
Lionel Piroth
CHU Dijon, Dijon, France
High SVR Regardless of Time to Suppression With ABT-450/r/Ombitasvir & Dasabuvir+RBV
David Wyles
University of California San Diego, La Jolla, CA, United States
The Paradox of Highly Effective Sofosbuvir Combo Therapy Despite Slow Viral Decline
Jérémie Guedj
IAME, UMR 1137, Inserm, F-75018; Univ Paris Diderot, Sorbonne Paris Cité, F-75018, Paris, France
Real-World Pharmaceutical Costs in the Simeprevir/Sofosbuvir Era: $164,485 per SVR4
Kian Bichoupan
Mount Sinai School of Medicine, New York, NY, United States
Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients
Cindy Zahnd
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study
David Wyles
University of California San Diego, La Jolla, CA, United States
Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1
Susanna Naggie
Duke Clinical Research Institute, Durham, NC, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
